• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV combination drug therapies: development and validation of an LC-MS-MS method for simultaneous quantitation of abacavir, dolutegravir, and lamivudine in rat matrices in support of toxicology studies.

作者信息

Silinski Melanie A Rehder, Gilliam Jennifer A, Apoian Julia, Fletcher Brenda L, Fernando Reshan A, Waidyanatha Suramya

机构信息

RTI International, PO Box 12194, Research Triangle Park, NC 27709, USA.

Division of Translational Toxicology, NIEHS, PO Box 12233, Research Triangle Park, NC 27709, USA.

出版信息

J Anal Toxicol. 2025 May 16;49(5):332-339. doi: 10.1093/jat/bkaf016.

DOI:10.1093/jat/bkaf016
PMID:40036775
Abstract

Abacavir (ABC), Dolutegravir (DTG), and Lamivudine (3TC) are part of a fixed-dose combination medication for the treatment of HIV. The three drugs offer different but complementary mechanisms of action by inhibiting reverse transcriptase and integrase, and ultimately inhibiting HIV replication. Due to the lack of information regarding long-term safety following in utero exposure, we are evaluating potential toxicity to offspring following in utero exposure to this combination therapy in Hsd:Sprague Dawley®SD® (HSD) rats, including cardiovascular toxicity and neurotoxicity. Generating internal exposure data are integral to putting toxicological findings into context. The objective of this work was to develop and validate a method to simultaneously quantitate ABC, DTG, and 3TC in rat matrices following exposure to this combination. The method used protein precipitation of plasma, fetal, placental, brain, or heart homogenate, followed by ultra-performance liquid chromatography-tandem mass spectrometry. In adult Sprague Dawley rat plasma, the method was linear (r ≥ 0.99) over the range 10/15/5 to 10,000/15,000/5000 ng/mL for ABC/DTG/3TC and recovery was ≥92% for all three analytes at all concentration levels. The limits of detection were 2.22, 3.69, and 0.978 ng/mL for ABC, DTG, and 3TC, respectively. Intra- and inter-day precision was ≤8.7% relative standard deviation (RSD), and relative error (RE) ≤±12.0% for standards prepared at 20/30/10, 400/600/200, and 5000/7500/2500 ng/mL. Matrix standards as high as 40/60/20 µg/mL could be diluted into the calibration range (RE≤±3.5% and RSD ≤2.4%). The method was evaluated for HSD rat maternal plasma and fetal, placental, brain, and heart homogenates (mean RE ≤±15.0% and RSD ≤8.6%). Analyte stability was demonstrated in extracted plasma for 2 days at different temperatures, and in various matrices stored at -80°C for at least 32 days (80-113% of Day 0 concentrations). These data demonstrate that this simple and efficient method is suitable for quantitation of ABC, DTG, and 3TC in rat matrices generated from toxicology studies. The method can easily be adapted to other biological matrices and species (e.g. human).

摘要

相似文献

1
HIV combination drug therapies: development and validation of an LC-MS-MS method for simultaneous quantitation of abacavir, dolutegravir, and lamivudine in rat matrices in support of toxicology studies.
J Anal Toxicol. 2025 May 16;49(5):332-339. doi: 10.1093/jat/bkaf016.
2
Effects of switching to dolutegravir/lamivudine from tenofovir alafenamide fumarate/emtricitabine/dolutegravir or abacavir/lamivudine/dolutegravir on body weight and lipid profile in Japanese people living with HIV.从替诺福韦艾拉酚胺富马酸盐/恩曲他滨/多替拉韦或阿巴卡韦/拉米夫定/多替拉韦转换为多替拉韦/拉米夫定对日本HIV感染者体重和血脂谱的影响。
J Infect Chemother. 2025 Feb;31(2):102544. doi: 10.1016/j.jiac.2024.10.012. Epub 2024 Oct 22.
3
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study.从多替拉韦/阿巴卡韦/拉米夫定转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺的疗效和安全性:一项3期随机、双盲、多中心、活性对照、非劣效性研究的开放标签扩展结果
Medicine (Baltimore). 2025 Feb 21;104(8):e41482. doi: 10.1097/MD.0000000000041482.
4
Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.多替拉韦、阿巴卡韦和拉米夫定固定剂量复方片剂的生物等效性及食物的影响。
J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):393-8. doi: 10.1097/QAI.0000000000000193.
5
Development and Validation of an Analytical Method for Quantitation of Bisphenol S in Rodent Plasma, Amniotic Fluid and Fetuses by UPLC-MS-MS.超高效液相色谱-串联质谱法测定啮齿动物血浆、羊水和胎盘中双酚 S 的分析方法的建立与验证
J Anal Toxicol. 2022 Mar 21;46(3):277-284. doi: 10.1093/jat/bkab008.
6
The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.静脉-动脉体外氧合和鼻胃管给药对阿巴卡韦、拉米夫定和多替拉韦药代动力学特征的影响:一例报告。
Antivir Ther. 2020;25(2):115-119. doi: 10.3851/IMP3355.
7
Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.在一项旨在辅助即时检测的随机对照、直接观察的药代动力学试验中,在停止药物摄入后,血浆和尿液中的替诺福韦、恩曲他滨、拉米夫定和度鲁特韦浓度。
J Antimicrob Chemother. 2024 Jul 1;79(7):1597-1605. doi: 10.1093/jac/dkae147.
8
Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.自2018年以来,接受过治疗的HIV感染者更换或重新开始抗逆转录病毒治疗方案的医疗资源利用情况及治疗费用。
J Manag Care Spec Pharm. 2024 Aug;30(8):817-824. doi: 10.18553/jmcp.2024.30.8.817.
9
Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms.通用型儿科阿巴卡韦/拉米夫定分散片在体重低于20公斤的泰国感染艾滋病毒幼儿中的药代动力学
Pediatr Infect Dis J. 2025 May 1;44(5):428-430. doi: 10.1097/INF.0000000000004683. Epub 2025 Jan 10.
10
Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.度鲁特韦/阿巴卡韦/拉米夫定固定剂量复方制剂作为西班牙HIV阳性患者初始治疗的成本效用分析
Farm Hosp. 2017 Sep 1;41(5):601-610. doi: 10.7399/fh.10808.